

Carbiotix AB announces the outcome of the exercise of warrants of series TO 2

On October 26, 2023, the exercise period for Carbiotix AB's ("Carbiotix" or "Company") warrants of series TO 2 ("TO 2") ended. No warrants were exercised. The background to the lack of interest is deemed to be that the price for exercise of warrants of series TO 2 during the exercise period has exceeded the prevailing share price.

During the exercise period from and including October 12, 2023, up to and including October 26, 2023, holders of warrants of series TO 2 have had the right to subscribe for one (1) new share in Carbiotix for each warrant of series TO 2 at a price of SEK1.50 per share. No warrants have been exercised and thus no share capital increase or change in the number of shares in the Company has taken place. The number of shares is thus still 20,736,229 and the share capital is SEK 2,073,622.90.

For more information about the warrants, please contact:

Sedermerna Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermerna.se
www.sedermerna.se

For more information, please contact:

Erik Deaner, VD
Telefon: +46 (0)73-867 30 85
E-post: erik.deaner@carbiotix.com

About Carbiotix

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome health through a portfolio of prebiotic modulators and diagnostic testing services.